Emma Magavern
Queen Mary University of London(GB)William Harvey Research Institute(GB)
Publications by Year
Research Areas
Pharmacogenetics and Drug Metabolism, Cardiomyopathy and Myosin Studies, Cardiovascular Effects of Exercise, Lipoproteins and Cardiovascular Health, Health Systems, Economic Evaluations, Quality of Life
Most-Cited Works
- → 2024 ESC Guidelines for the management of chronic coronary syndromes(2024)1,940 cited
- → Identification of the functional core of the influenza A virus A/M2 proton-selective ion channel(2009)170 cited
- → Cardiopulmonary Responses and Prognosis in Hypertrophic Cardiomyopathy(2015)104 cited
- → Design and Pharmacological Characterization of Inhibitors of Amantadine-Resistant Mutants of the M2 Ion Channel of Influenza A Virus(2009)104 cited
- → 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy(2025)81 cited
- → Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy(2017)67 cited
- → Health equality, race and pharmacogenomics(2021)63 cited
- → Prevalence and Clinical Correlates of Right Ventricular Dysfunction in Patients With Hypertrophic Cardiomyopathy(2013)57 cited
- → 2025 ESC Clinical Consensus Statement on mental health and cardiovascular disease: developed under the auspices of the ESC Clinical Practice Guidelines Committee(2025)56 cited
- → The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy(2021)48 cited